comparemela.com

Latest Breaking News On - Kras status - Page 1 : comparemela.com

Avutometinib Plus Defactinib Demonstrates Promising Activity in Recurrent LGSOC

Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the RAMP 201 trial.

Sweegen obtains FEMA GRAS status for sweet protein brazzein technology

Sweegen has revealed that its “highly sought-after” sweet protein Ultratia brazzein technology has received GRAS status from the FEMA.

Innophos launches non-alumium phosphate for industrial bakers seeking to clean up labels

The specialist in leavening agents for the bakery industry has launched a non-aluminium alternative to the traditional sodium aluminum phosphate (SALP) for bakers looking to meet the consumer preference for clean label.

To reach its true potential : Ingredient bigwigs create consortium to drive EU recognition for low-calorie sweetener

Allulose is totally on point in today’s health-and wellness-focused world – poised to support any government and industry effort to achieve sugar reduction goals to combat the rising obesity crisis. With just 10% of the calories of standard sugar, it will help UK product developers to conform with the new HFSS (high in fat, sugar and sodium) guidelines set to come into effect next October.

To reach its true potential : Ingredient bigwigs create consortium to drive EU recognition for low-calorie sweetener

Allulose is totally on point in today’s health-and wellness-focused world – poised to support any government and industry effort to achieve sugar reduction goals to combat the rising obesity crisis. With just 10% of the calories of standard sugar, it will help UK product developers to conform with the new HFSS (high in fat, sugar and sodium) guidelines set to come into effect next October.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.